Madrigal Pharmaceuticals, Inc. (MDGL) stock
MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/304% above fair value
$398.08−23.91 (-5.67%)
Close on Nov 18, 2026Market cap $9.20BP/E –Yield –
Madrigal Pharmaceuticals price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Madrigal Pharmaceuticals's price to sales ratio was 7.8× on Nov 11, 2026, against 18.3× a year earlier. Over the last 2 years it ranged from 7.7× to 352.1×, with a median of 18.9×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 7.8× | −10.1 |
| 2025 | Dec 31, 2025 | 17.9× | −69.7 |
| 2024 | Dec 31, 2024 | 87.6× | – |
See a number that looks wrong?